Community Cancer Centers Treating More HPV-Related Head, Neck Cancer
11 Jan 2024
Clinical Result
THURSDAY, Jan. 11, 2024 -- Treatment of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma has recently shifted to community cancer centers, with an increase in the proportion of nonsurgical treatment and worse overall survival versus patients treated at academic cancer centers, according to a study published online Jan. 3 in the Journal of the National Cancer Institute.
Danielle R. Trakimas, M.D., from Johns Hopkins Hospital in Baltimore, and colleagues used the U.S. National Cancer Database to identify 20,298 patients with a diagnosis of HPV-related oropharyngeal squamous cell carcinoma (2010 to 2019) who underwent treatment at a community cancer center or academic cancer center.
The researchers found that the proportion of patients treated at community cancer centers significantly increased by 10 percent during the study period. Concurrently, the proportion of patients undergoing primary nonsurgical treatment increased from 62.1 to 73.7 percent, with nonsurgical treatment significantly more likely for patients treated at community cancer centers versus academic cancer centers (adjusted odds ratio [aHR], 1.20). Worse survival was seen among patients treated at community cancer centers (aHR, 1.19), particularly for patients receiving primary nonsurgical treatment (aHR, 1.22).
"Given these findings, additional resources should be directed toward identifying patients who may benefit from surgical treatment and toward ensuring equal access to all available treatment modalities for optimal patient autonomy and outcomes," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.